Menlo Park, Calif. and Dallas, Texas – November 2, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave

Menlo Park, Calif. and Dallas, Texas – September 26, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave

Menlo Park, Calif. and Dallas, Texas – September 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave

Menlo Park, Calif. and Dallas, Texas – September 12, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave

MENLO PARK, Calif. & DALLAS–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics,

Menlo Park, Calif. and Dallas, Texas – July 6, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave

– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing

Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to

ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) formulation of DNAI1 mRNA was successfully and directly delivered to lungs as an inhaled aerosol with no

Menlo Park, Calif. and Dallas, Texas – May 10, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ